Opinion
Video
Author(s):
Stephanie Graff, MD, concludes the discussion with thoughts on endocrine therapies in development for patients with ER+/HER2- metastatic breast cancer.
SH-105 Gains FDA Approval for Breast, Ovarian Cancers
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
Breast Cancer Risk Reduced by Bariatric Surgery in Patients With High Insulin Levels
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
Neighborhood Deprivation Linked to Increased Breast Cancer Deaths for White Women, but Not Black Women
Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy